Key result
Beta-blockers show no 1-year mortality benefit in post-AMI patients without HF or LV dysfunction.
Why the study?
Does β-blocker use reduce mortality in survivors of acute myocardial infarction without heart failure or ventricular dysfunction?
Does β-blocker use reduce mortality in survivors of acute myocardial infarction without heart failure or ventricular dysfunction?
In survivors of acute myocardial infarction without heart failure or left ventricular systolic dysfunction, routine beta-blocker use was not associated with improved 1-year survival.
Answers are grounded in this paper and cite their sources.
β-Blockers not associated with lower 1-year mortality post-AMI without HF/LVSD; leaves open need for RCTs before practice change.
Among survivors of hospitalization with AMI who did not have HF or LVSD as recorded in the hospital, the use of β-blockers was not associated with a lower risk of death at any time point up to 1 year. (β-Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure; NCT02786654).
No takes yet. Share an insight, caveat, or question.
Dondo et al. (2017) studied this question. In patients without heart failure or left ventricular dysfunction after acute myocardial infarction, β-blockers were not associated with reduced mortality up to 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: